For Harvard computer scientists, entrepreneurship is often a fulfilling extension of their cutting-edge research.

Protein matrix vaccines, HDAC inhibitors, photocatalysis, supercharged proteins, and more.

UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

Cambridge-based startup is commercializing technology from the Harvard lab of George Whitesides.